Sida Cordifolia (Bala) — Benefits Deep Dive

Read this in light of the hub’s central warning, not after it. Sida cordifolia genuinely contains ephedrine and pseudoephedrine — the same prescription-grade stimulant alkaloids the FDA removed from the supplement market in 2004 when they were sold as ephedra. The main hub page covers that mechanism, the FDA history, and the cardiovascular case data in full, and nothing on these four pages is meant to soften it. What these four pages add is the rest of the chemistry: this plant also contains a second, structurally unrelated alkaloid family, several non-alkaloid compounds with their own real pharmacology, and one traditional-use route (topical) that largely escapes the systemic hazard altogether. Sorting which claim traces to which compound, by which route, is the actual content of “what are the benefits of bala” — a question that cannot be honestly answered without the hazard sitting in the same sentence.

The pattern that emerges, claim by claim, is this plant’s clearest demonstration on this site of a doctrine this leg was built to test: when a plant carries a documented pharmacological hazard, ask whether each proposed benefit shares that exact mechanism or a genuinely different one — and say which, at the point of the claim, every time. Here the answer is not one-size-fits-all. The respiratory claim turns out to be more mechanistically real than a first pass suggests, and for exactly that reason more clearly tied to the same danger. The “strength and energy” claim splits cleanly into a marketed half that is the stimulant story again, and an unmarketed half — nerve-pain relief, bone density — that traces to entirely different compounds. Topical use is the one place benefit and hazard genuinely separate, by chemistry and by route both. And the plant’s single most consequential modern use, weight loss, turns out to rest on no human evidence at all, propped up by a market-sample identity problem that makes even “buy the real plant and accept the known risk” unreliable advice.

None of the four pages below repeats the hub’s ephedrine case in detail. All four assume you have read it, or link back to the exact section that applies.

Table of Contents

1. Deep-Dive Articles
2. How to Read This Leg
3. Five Things Worth Knowing
4. Evidence Ledger at a Glance
5. Who Should Not Use Any Form of This Plant
6. Key Research
7. External Resources
8. Connections

Deep-Dive Articles

Back to Table of Contents

How to Read This Leg

Five habits run through all four pages.

1. Every claim is checked against the hub’s own hazard mechanism, at the point of the claim. Not once in a preamble — a reader arriving mid-page, or quoting one line, should be able to see immediately whether the benefit under discussion shares the cardiovascular-alkaloid mechanism or not.
2. Borrowed evidence is labelled where it is borrowed. Vasicine’s bronchodilator pharmacology comes mainly from Adhatoda vasica, a related but different plant, even though the compound itself is confirmed in Sida cordifolia by direct assay. Rosmarinic acid’s antibacterial activity is real in this plant but the compound is common across many others. Each is flagged at the citation, not once for the whole page.
3. Absent, negative, and old-but-real are kept apart. “No clinical trial exists” (weight loss) is a different, more damning statement than “one small confounded trial exists and was positive” (neuropathic pain) — collapsing the two would flatter the untested claim and undersell the tested one.
4. Numbers we cannot stand behind are refused out loud. The vasicine-content arithmetic states the measured dose and then explicitly declines to say whether it is pharmacologically meaningful, because no human dose-response data exists to check that against.
5. Species identity is checked, not assumed. One page relies on a direct DNA-barcoding study of market samples rather than taking a product label at its word — and what it found changes the entire risk calculation for a consumer.

All four pages cite exclusively through PubMed topic searches built from each paper’s real title, with author, journal and year given in the prose — the same practice as the rest of this site’s Benefits legs, so a link can never silently resolve to the wrong record.

Five Things Worth Knowing

If you read nothing else in this leg:

1. This plant has two unrelated alkaloid families, and almost no marketing distinguishes them. Ephedrine and pseudoephedrine are sympathomimetic stimulants — the hub’s entire hazard case. Vasicine, vasicinone and a related compound isolated from this plant specifically are quinazoline alkaloids with bronchodilator, analgesic and anti-inflammatory activity through completely different receptors. “This plant has alkaloids” is not one fact with one risk.
2. The one dedicated CNS study found a sedative effect, not a stimulant one. A high-dose whole-leaf extract reduced spontaneous activity in mice — directly contradicting the “energising tonic” marketing this plant is sold under, at the one point where that marketing claim was actually tested.
3. The best modern evidence on this plant is mostly for claims nobody markets. A 2024 mechanism study ties root extract, via betaine, to a real nerve-pain pathway. A 2022 study ties root and leaf extract, via polyphenols, to bone formation. Neither trades on ephedrine. Neither shows up on a supplement label selling “energy” or “vitality.”
4. Topical use is the one clean separation of benefit from hazard. Wound-healing and antibacterial activity trace to phenolics and rosmarinic acid, and the hub’s own Forms section already ranks external oils as the lowest-systemic-absorption form — chemistry and route agreeing for once.
5. For weight loss — the claim that actually sells this plant — there is no human trial, and a DNA-barcoding study found that essentially none of what is sold under this name in the raw-drug market is genuinely this species, with the commonest substitute carrying roughly six times more ephedrine. This is covered in full on the weight-loss page and may be the single most important finding in this entire leg.

Evidence Ledger at a Glance

Ranked by strength and honesty of evidence rather than by fame, across all four pages.

1. Direct market analysis — the decisive finding. DNA barcoding of raw-drug market samples found zero percent genuine Sida cordifolia; the commonest substitute (Sida acuta, 36% of samples) carries roughly six-fold more ephedrine.
2. Direct phytochemical quantification. Vasicine confirmed by HPLC in Sida cordifolia root, at the highest level of eight Sida species tested.
3. Human, randomised, placebo-controlled — but for a different plant in the same drug class. Synephrine (bitter orange): blood pressure and heart rate up, weight loss not significant. Ephedrine/ephedra (hub): modest weight loss, doubled-to-tripled adverse-symptom risk.
4. Human, randomised, placebo-controlled — for this plant, but formula-confounded. A Phyllanthus niruri + Sida cordifolia combination reduced diabetic neuropathy symptoms versus placebo; the result cannot be attributed to Sida cordifolia alone.
5. Human, single-agent, registered but unresulted. A recruiting trial of Sida cordifolia oil alone for frozen shoulder.
6. Animal, mechanistic, alkaloid-independent, recent. Neuropathic pain reduction via betaine/NMDA signalling (2024); bone formation via polyphenols in an ovariectomy model (2022); dedicated wound-healing mechanism work (2019); antibacterial compound identification, rosmarinic acid against MRSA (2022).
7. Animal, replicated across independent, unconnected labs. General analgesic/anti-inflammatory activity — Bangladesh, India, Brazil, Burkina Faso.
8. Animal, borrowed pharmacology, clearly labelled. Vasicine’s bronchodilator mechanism, established mainly in Adhatoda vasica and in synthetic derivatives, not in Sida cordifolia extract itself.
9. Genuine contradiction, reported rather than hidden. The plant’s only dedicated CNS study found a sedative, not stimulant, behavioural profile.
10. Absent, not refuted. Any human trial of this plant for weight loss, wound healing, respiratory disease, bone density, or general pain, as a single agent.
11. Refused. A therapeutic-equivalence claim for the measured vasicine dose in a traditional decoction, because no human dose-response data exists to check it against; any market-share estimate for how much sold product is genuine plant material.
12. Safety facts, established mainly on the hub. The FDA’s 2004 ephedrine-alkaloid rule names Sida cordifolia explicitly; WADA prohibits ephedrine above a defined threshold; concentration is unpredictable from label to label.

Who Should Not Use Any Form of This Plant

The hub’s Cautions and Contraindications section is the full list — pregnancy, high blood pressure, arrhythmia, coronary disease, stroke history, hyperthyroidism, glaucoma, prostate obstruction, anxiety and seizure disorders, MAOI use, competitive sport — and applies to any concentrated oral form covered anywhere in this leg. Two additions from this leg’s own research, worth adding to that list rather than repeating it:

• Anyone on anticoagulant or antiplatelet medication — one animal study found antithrombotic and platelet-lowering activity in this plant (discussed on the wound-healing page), a mechanism separate from the cardiovascular-stimulant one and worth knowing about before combining any concentrated preparation with a bleeding-risk drug.
• Anyone buying a weight-loss, thermogenic or energy product listing this ingredient — per the weight-loss page, market-sample testing found the labelled species is rarely what such raw material actually is, and the likely substitute carries more of the alkaloid the hub warns about, not less.

Key Research

Grouped by theme. Every entry gives the paper’s title, journal and year in prose and links to a PubMed topic search built from that title, so a link can never resolve to the wrong record.

1. Two alkaloid families and the respiratory claim

1. Simultaneous determination of vasicine and vasicinone by High-performance liquid chromatography in roots of eight Sida species. Subramanya MD et al., Ayu, 2016. PubMed search
2. A bronchodilator alkaloid (vasicinone) from Adhatoda vasica Nees. Amin AH, Mehta DR, Nature, 1959. PubMed search
3. Vasicine Attenuates Allergic Asthma by Suppressing Mast Cell Degranulation and Th2 Inflammation… Qu L et al., Pharmaceuticals, 2026. PubMed search
4. Ephedrae herba: a comprehensive review of its traditional uses, phytochemistry, pharmacology, and toxicology. Zheng Q et al., Journal of Ethnopharmacology, 2023. PubMed search
5. Full theme, with the arithmetic and the drug-development history — Respiratory and Bronchodilator Use.

2. Nerves, strength and the CNS contradiction

1. CNS pharmacological effects of the hydroalcoholic extract of Sida cordifolia L. leaves. Franco CI et al., Journal of Ethnopharmacology, 2005. PubMed search
2. Sida cordifolia L. attenuates behavioral hypersensitivity by interfering with KIF17-NR2B signaling in rat model of neuropathic pain. Tiwari V, Hemalatha S, Journal of Ethnopharmacology, 2024. PubMed search
3. A randomized placebo-compared study… Phyllanthus niruri Linn. Plus Sida cordifolia Linn. in patients of diabetic sensory polyneuropathy. Patel MV et al., Journal of Ayurveda and Integrated Medicine, 2022. PubMed search
4. Ethanolic extract from the root and leaf of Sida cordifolia promotes osteoblast activity and prevents ovariectomy-induced bone loss in mice. Patel K et al., Phytomedicine, 2022. PubMed search
5. Full theme, with the analgesic literature and the antioxidant/hepatic evidence — Rasayana, Strength and the Nervous System.

3. Wound healing and topical/antimicrobial use

1. Sida cordifolia accelerates wound healing process delayed by dexamethasone in rats: Effect on ROS and probable mechanism of action. Kumar S et al., Journal of Ethnopharmacology, 2019. PubMed search
2. Wound healing activity of Sida cordifolia Linn. in rats. Pawar RS et al., Indian Journal of Pharmacology, 2013. PubMed search
3. Extracts of Sida cordifolia contain polysaccharides possessing immunomodulatory activity and rosmarinic acid compounds with antibacterial activity. Iqbal H et al., BMC Complementary Medicine and Therapies, 2022. PubMed search
4. Full theme, including the retracted-paper citation-hygiene note — Wound Healing and Topical Use.

4. Weight loss, the sibling botanical, and market identity

1. DNA barcoding for species identification from dried and powdered plant parts: a case study with authentication of the raw drug market samples of Sida cordifolia. Vassou SL et al., Gene, 2015. PubMed search
2. The Safety and Efficacy of Citrus aurantium (Bitter Orange) Extracts and p-Synephrine: A Systematic Review and Meta-Analysis. Koncz D et al., Nutrients, 2022. PubMed search
3. Unexplained Supraventricular Tachycardia and Myocardial Injury After Bitter Orange Supplement Use in a Young Woman. Plaitis A et al., JACC: Case Reports, 2026. PubMed search
4. Cardiovascular toxicity associated with supplement use. Corcoran J, Clinical Toxicology, 2025. PubMed search
5. Full theme, with the trial-design gap analysis — Weight-Loss Trials and Marketing.

5. Identity, regulation and general pharmacology

1. The genus Sida L. – A traditional medicine: its ethnopharmacological, phytochemical and pharmacological data for commercial exploitation in herbal drugs industry. Dinda B et al., Journal of Ethnopharmacology, 2015. PubMed search
2. Densitometric method for assessment of six specialized metabolites in four Sida sp. and its congener Abutilon indicum. Rahate SP et al., Journal of Pharmaceutical and Biomedical Analysis, 2024. Also cited on the main hub. PubMed search
3. Quality by design-based optimization of Soxhlet extraction and identification of ephedrine by a HPTLC method for Sida rhombifolia and Sida Cordifolia. Imran M et al., Biomedical Chromatography, 2022. PubMed search
4. Topic search covering the whole plant — Sida cordifolia, all indications.

Back to Table of Contents

External Resources

• US Federal Register — the 2004 ephedrine-alkaloid final rule, which explicitly names Sida cordifolia as a botanical source of the alkaloids it prohibits.
• NIH National Center for Complementary and Integrative Health — Ephedra. Plain-language background on the drug class this plant belongs to.
• WADA Prohibited List. Ephedrine and pseudoephedrine thresholds for competitive athletes.
• NIH Office of Dietary Supplements. Independent fact sheets on supplement ingredients and safety.
• Plants of the World Online (Royal Botanic Gardens, Kew). The authority for checking Sida species names before trusting any label — directly relevant given the identification findings on the weight-loss page.
• US FDA — Dietary Supplements. How to report an adverse event, and current guidance on supplement safety.
• PubMed. Every citation across this leg is a live search here.

Connections

• All Herbs
• Sida Cordifolia (Bala) — Main Page — the full ephedrine/pseudoephedrine safety case, FDA history and dosage guidance this entire leg is built on.
• Respiratory and Bronchodilator Use — two alkaloid families, one traditional claim.
• Rasayana, Strength and the Nervous System — the contradiction, the nerve-pain mechanism, the bone-density reframing.
• Wound Healing and Topical Use — where benefit and hazard genuinely separate.
• Weight-Loss Trials and Marketing — zero human trials, and what you are actually buying.
• Ashwagandha — the genuinely calming, trial-supported adaptogen bala is marketed beside but does not resemble.
• Ashwagandha Benefits
• Licorice — another traditional herb with a real, dose-dependent blood-pressure problem.
• Ginseng — a stimulating tonic herb with a far better-characterised safety profile.
• Cardiology — the harm side of the plant’s primary alkaloid mechanism.
• Hypertension
• Asthma — what actually treats it.
• Obesity — what actually treats it, and the evidence bar a real intervention has to clear.
• Toxins — how this site covers substances whose risk outweighs their benefit.
• Lab Tests — blood pressure, thyroid function and an ECG are the checks that matter before any stimulant herb.

Back to Table of Contents